Stallergenes Greer Announces Global Agreement With Nestlé Regarding the Peanut Allergy Oral Immunotherapy Treatment Palforzia®
4.9.2023 08:38:00 EEST | Business Wire | Press release
Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announced today that it has signed global agreements with Nestlé to harness the peanut allergy oral immunotherapy treatment Palforzia®. The transaction was closed upon signing.
Peanut allergy currently affects approximately 2% of the general population of Western nations1, and the prevalence of peanut allergy doubled among children between 2005 and 20152. The difficulty of avoiding peanuts, combined with the severity of allergic reactions, including anaphylaxis, shows the need for effective treatment3.
“We are delighted about this agreement with Nestlé which marks a significant milestone for Stallergenes Greer,” stated Michele Antonelli, CEO of Stallergenes Greer. “Palforzia®, with its robust efficacy and safety profile, is currently the only available approved treatment for inadvertent exposure to peanuts. By entering the food allergy space, Stallergenes Greer becomes the first allergen immunotherapy company to offer both respiratory and food allergy treatments and demonstrates its lasting commitment to provide patients and the medical community with innovative allergen immunotherapy treatments.”
Nestlé will receive milestone payments and ongoing royalties from Stallergenes Greer. There will be a customary transition period to ensure business continuity and give patients uninterrupted access to the treatment.
With this transaction, Stallergenes Greer further strengthens its presence in the field of AIT. The company’s portfolio offers patients and healthcare professionals precise personalised AIT treatments which cover a broad range of administration modes and can be tailored to the individual needs of patients with allergies: sublingual oral solutions, tablets, and injectables for respiratory allergies; and powder to be consumed with semi-solid foods for peanut allergies.
ABOUT PALFORZIA ®
Palforzia® is an oral immunotherapy treatment approved for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy by the U.S. Food and Drug Administration (FDA), the European Commission (EC), the Medicines and Healthcare products Regulatory Agency (MHRA) in the U.K., and by Swissmedic. Use of Palforzia® may be continued in patients 18 years of age and older.
Palforzia® is not indicated for the emergency treatment of allergic reactions, including anaphylaxis, and must always be used in conjunction with a peanut-avoidant diet.
ABOUT STALLERGENES GREER INTERNATIONAL AG
Headquartered in Baar (Switzerland), Stallergenes Greer International AG is a global healthcare company specialising in the diagnosis and treatment of allergies through the research, development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer International AG is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France). For more information, visit www.stallergenesgreer.com.
1 The global burden of illness of peanut allergy: A comprehensive literature review. Jay A. Lieberman, Ruchi S Gupta, Rebecca C. Knibb, Tmirah Haselkorn, Stephen Tilles, Douglas P. Mack, and Guillaume Pouessel. Online: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8247890/. Accessed August 31, 2023
2 Du Toit G, et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut Allergy. N Engl J Med 2015; 372: 803-13. Accessed August 31, 2023.
3 Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol. 2001;107:191-3. Accessed August 31, 2023.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230903080283/en/
Contact information
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Resurgens Technology Partners Invests in Qarma to Advance the Future of Quality and Compliance13.8.2026 16:00:00 EEST | Press release
Resurgens Technology Partners (“Resurgens”), a software-focused private equity firm, today announced its partnership with Qarma, a leading global provider of AI-powered quality and compliance software for brands, retailers, and manufacturers managing complex, global supply chains. Qarma has built a platform that combines best-practice quality and compliance with hands-on execution where it matters most, on the factory floor. Qarma will continue to be led by its Co-founders, CEO Jacob Nedergaard and CTO Søren Mønsted. Founded in 2016, Qarma serves customers across industries, including furniture and home, apparel, consumer goods, and electronics. Its platform connects quality and compliance teams, sourcing professionals, suppliers, and inspectors. Over the past decade, Qarma has built one of the industry’s deepest operational quality platforms, combining best-practice workflows with software designed to work natively on factory floors worldwide. This unique operational foundation has ge
Tecnotree allekirjoitti 17,5 miljoonan Yhdysvaltain dollarin monivuotisen sopimuksen nykyisen teleoperaattoriasiakkaan kanssa Amerikan alueella13.8.2026 15:04:00 EEST | Tiedote
Tecnotree, joka on maailmanlaajuinen 5G- ja tekoälynatiivien digitaalisten BSS-ratkaisujen sekä teleoperaattoreille suunnattujen digitaalisen transformaation ratkaisujen toimittaja, ilmoitti eilen allekirjoittaneensa uuden monivuotisen ja usean alueen kattavan sopimuksen nykyisen teleoperaattoriasiakkaan kanssa Amerikan alueella. Sopimus kuvastaa Tecnotreen jatkuvaa painotusta pitkäaikaisten asiakassuhteiden laajentamiseen yhtiön 5G- ja tekoälynatiivien digitaalisten alustojen ja palvelujen avulla, jotka auttavat teleoperaattoreita uudistamaan liiketoimintaansa, nopeuttamaan palveluinnovaatioita ja parantamaan asiakaskokemusta. Tecnotree jatkaa operaattoreiden muuttuvien digitaalisen transformaation painopisteiden tukemista maailmanlaajuisesti. ”Amerikan alue on Tecnotreelle edelleen tärkeä markkina-alue, jolla yhtiö jatkaa teleoperaattoreiden tukemista ratkaisuilla, jotka yksinkertaistavat toimintaa, mahdollistavat liiketoiminnan ketteryyden ja luovat kestävää arvoa seuraavan sukupolv
Vantage Data Centers and Nebius Expand UK AI Infrastructure with First Deployment in South Wales AI Growth Zone13.8.2026 15:00:00 EEST | Press release
Vantage Data Centers, a leading global provider of hyperscale data center campuses, and Nebius (Nasdaq: NBIS), the AI cloud company, today announced an agreement to deploy high-density, NVIDIA-powered AI infrastructure at Vantage’s CWL1 campus in Newport, Wales. The deployment represents the first announced commercial capacity commitment in the South Wales AI Growth Zone and will support growing UK demand for domestic AI compute capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813253918/en/ CWL13 data center at Vantage’s Newport, Wales, campus. Under the agreement, Nebius will lease high-density capacity at CWL1 to support AI training, inference, agentic AI and enterprise AI workloads, serving enterprises, researchers, startups and public sector organizations seeking access to advanced AI infrastructure. This capacity is part of Nebius’ broader UK expansion and commitment to scale domestic AI compute capacity. In
SBC Medical Group Holdings Reports Second Quarter 2026 Financial Results13.8.2026 13:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the second quarter of fiscal year 2026 (the three months ended June 30, 2026) and the first half of fiscal year 2026 (the six months ended June 30, 2026). Second Quarter 2026 Financial Highlights Total revenues were $49 million, an increase of 13% year-over-year. Net income attributable to SBC Medical was $11 million, an increase of 335% year-over-year. Net income margin was 22%, an increase of 16 percentage points year-over-year. Adjusted EBITDA1 was $20 million, an increase of 32% year-over-year. Adjusted EBITDA margin1 was 41%, an increase of 6 percentage points year-over-year. Basic EPS was $0.10 for the three months ended June 30, 2026, an increase of 400% year-over-year. The Company believ
Unimed Expands Maritime Healthcare Platform with Growing Adoption of Telemed Plus13.8.2026 12:00:00 EEST | Press release
Universal Maritime Solutions (“Unimed” or “the Company”), a leading provider of maritime healthcare, medical supply, and crew wellbeing solutions and a portfolio company of ZCG Private Equity, the private equity fund management platform of Z Capital Group, LLC (“ZCG”), today announced that Bahri, one of the Middle East’s leading maritime operators, has expanded its relationship with Unimed by enrolling in its Telemed Plus premium service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813787745/en/ The agreement builds on a longstanding relationship between the companies through Unimed’s MedScale medical supply and medical chest management program and marks another important milestone in the continued rollout of Unimed’s Telemed Plus platform, launched in 2024. The expansion underscores the growing adoption of Unimed’s integrated healthcare platform by leading global maritime operators while demonstrating the increasing v
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom